公开(公告)号：US08846604B2

公开(公告)日：2014-09-30

申请号：US13601626

申请日：2012-08-31

Applicant: Hogne Hallaraker ,  Jan Remmereit ,  Alvin Berger

Inventor： Hogne Hallaraker ,  Jan Remmereit ,  Alvin Berger

IPC: A23D9/00 ,  A23D9/013 ,  A23D9/04 ,  A23J7/00 ,  A61K9/20 ,  A23K1/16 ,  A61K31/685 ,  A23K1/18 ,  A61K47/44 ,  A61K9/00 ,  A61K9/06 ,  A23L1/30 ,  A61K47/22 ,  A61K9/12 ,  A61K31/683

CPC classification number: A61K31/661 ,  A23K20/158 ,  A23K50/60 ,  A23K50/80 ,  A23L33/115 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/12 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/202 ,  A61K31/683 ,  A61K31/685 ,  A61K47/22 ,  A61K47/44 ,  C11B1/10 ,  Y02A40/818 ,  A61K2300/00

Abstract: The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.

Abstract translation: 本发明提供包含具有高二十二碳六烯酸（DHA）含量的磷脂的脂质组合物，该组合物优选从天然来源中提取。 脂质组合物是高度生物可利用的DHA的优良来源，它们可以用于口服运送车辆，膳食补充剂，功能食品等。

公开(公告)号：US10154979B2

公开(公告)日：2018-12-18

申请号：US14774432

申请日：2014-03-10

Applicant: Jan Remmereit ,  Alvin Berger

Inventor： Jan Remmereit ,  Alvin Berger

IPC: A61K31/20 ,  A61K31/202 ,  A61K31/19 ,  A61K31/201 ,  A23D9/007 ,  A23D9/013 ,  A61K9/00 ,  A23K20/158 ,  A23L33/12

Abstract: Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of structured lipid compositions containing sciadonic and/or pinoleic acid alone or in combination with other bioactive fatty acids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, conjugated linoleic acid, and non-β-oxidizable fatty acid analoges such as tetradecylthioacetic acid.

公开(公告)号：US20160022622A1

公开(公告)日：2016-01-28

申请号：US14774432

申请日：2014-03-10

Applicant: Jan REMMEREIT ,  Alvin Berger

Inventor： Jan Remmereit ,  Alvin Berger

IPC: A61K31/202 ,  A23L1/30 ,  A61K9/00 ,  A61K31/19 ,  A61K31/201

CPC classification number: A61K31/202 ,  A23D9/007 ,  A23D9/013 ,  A23K20/158 ,  A23L33/12 ,  A23V2002/00 ,  A61K9/0053 ,  A61K31/19 ,  A61K31/201 ,  A61K2300/00

Abstract: Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of structured lipid compositions containing sciadonic and/or pinoleic acid alone or in combination with other bioactive fatty acids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, conjugated linoleic acid, and non-β-oxidizable fatty acid analogues such as tetradecylthioacetic acid.

Abstract translation: 本文提供了涉及含有生物活性脂肪酸的脂质组合物的技术，特别但并非排他地涉及与单独或与其它生物活性脂肪酸组合的含有sciadonic和/或亚油酸的结构化脂质组合物的生产和使用相关的组合物和方法，包括 但不限于二十碳五烯酸，二十二碳六烯酸，共轭亚油酸和非 - 可氧化的脂肪酸类似物如十四烷基硫代乙酸。

公开(公告)号：US20150018570A1

公开(公告)日：2015-01-15

申请号：US14498548

申请日：2014-09-26

Applicant: Hogne Hallaraker ,  Jan Remmereit ,  Alvin Berger

Inventor： Hogne Hallaraker ,  Jan Remmereit ,  Alvin Berger

IPC: C11B1/10

CPC classification number: A61K31/661 ,  A23K20/158 ,  A23K50/60 ,  A23K50/80 ,  A23L33/115 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/12 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/202 ,  A61K31/683 ,  A61K31/685 ,  A61K47/22 ,  A61K47/44 ,  C11B1/10 ,  Y02A40/818 ,  A61K2300/00

Abstract: The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.

Abstract translation: 本发明提供包含具有高二十二碳六烯酸（DHA）含量的磷脂的脂质组合物，该组合物优选从天然来源中提取。 脂质组合物是高度生物可利用的DHA的优良来源，它们可以用于口服运送车辆，膳食补充剂，功能食品等。

公开(公告)号：US20140051601A1

公开(公告)日：2014-02-20

申请号：US13958158

申请日：2013-08-02

Applicant: Arul M. Chinnaiyan ,  Arun Sreekumar ,  Matthew W. Mitchell ,  Kay A. Lawton ,  Alvin Berger ,  Christopher Beecher

Inventor： Arul M. Chinnaiyan ,  Arun Sreekumar ,  Matthew W. Mitchell ,  Kay A. Lawton ,  Alvin Berger ,  Christopher Beecher

IPC: G01N33/483 ,  G01N33/493

CPC classification number: G01N33/4833 ,  G01N33/493 ,  G01N33/57434 ,  G01N33/6806 ,  Y02A90/22 ,  Y02A90/26

Abstract: The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer.

Abstract translation: 本发明涉及癌症标志物。 特别地，本发明提供在前列腺癌中差异存在的代谢物。

公开(公告)号：US20100279956A1

公开(公告)日：2010-11-04

申请号：US12771729

申请日：2010-04-30

Applicant: Bruce J. MC CREEDY, JR. ,  Alvin Berger ,  YunFu Hu ,  Satish C. Kalhan

Inventor： Bruce J. MC CREEDY, JR. ,  Alvin Berger ,  YunFu Hu ,  Satish C. Kalhan

IPC: A61K31/7004 ,  C12Q1/00 ,  G01N33/53 ,  C12Q1/02 ,  G01N33/00 ,  G01N30/02 ,  A61K31/66 ,  A61K31/60 ,  A61K31/56 ,  A61K31/415 ,  A61K31/195

CPC classification number: G01N33/6893 ,  G01N2500/00 ,  G01N2570/00 ,  G01N2800/085 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/60 ,  H01J49/0027 ,  Y10T436/143333 ,  Y10T436/163333 ,  Y10T436/200833

Abstract: The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.

Abstract translation: 本发明提供脂肪肝疾病的多种生物标志物，包括脂肪变性和脂肪性肝炎。 本发明还提供了使用生物标志物的各种方法，包括用于诊断脂肪肝疾病的方法，确定脂肪肝疾病倾向的方法，监测脂肪肝疾病进展/消退的方法，评价组合物治疗脂肪的功效的方法 肝脏疾病，筛选脂肪肝疾病生物标志物活性组合物的方法，脂肪肝疾病治疗方法以及基于脂肪肝疾病生物标志物的其他方法。

公开(公告)号：US07178497B2

公开(公告)日：2007-02-20

申请号：US10908393

申请日：2005-05-10

Applicant: Alvin Berger ,  Vince Solferino

Inventor： Alvin Berger ,  Vince Solferino

IPC: F02B75/00

CPC classification number: B60W30/20 ,  B60W10/06 ,  B60W10/08 ,  B60W10/30

Abstract: A system and method for managing inertial torque reaction of a powertrain include a selectively engageable counter-rotating component to reduce or eliminate torque reaction on stationary powertrain structure. Selectively engageable counter-rotating inertia may be provided by a simple inertial mass or by an electrical machine functioning as an integral starter/generator (ISG) to provide vehicle launch assist, regenerative braking of the vehicle, and engine cranking. Embodiments include gear-driven, chain-driven, and belt-driven counter-rotating inertias selectively coupled for counter-rotation relative to the crankshaft by a clutch, a belt-driven pulley assembly, or chain-driven intermediate shaft assembly with a hydraulically actuated coupling pin.

Abstract translation: 用于管理动力系的惯性力矩反作用的系统和方法包括可选择性地接合的反向旋转部件，以减少或消除固定动力系结构上的扭矩反作用。 可以通过简单的惯性质量或用作整体式起动/发电机（ISG）的电机来提供选择性地接合的反向旋转惯性，以提供车辆启动辅助，车辆的再生制动和发动机起动。 实施例包括齿轮驱动，链条驱动和皮带驱动的反向旋转惯性，其通过离合器，皮带从动皮带轮组件或链驱动的中间轴组件选择性地联接以相对于曲轴进行反向转动，所述中间轴组件具有液压致动 连接销。

公开(公告)号：US20130309697A1

公开(公告)日：2013-11-21

申请号：US13950581

申请日：2013-07-25

Applicant: Matthew W. Mitchell ,  Alvin Berger ,  Kay A. Lawton ,  Christopher Beecher

Inventor： Matthew W. Mitchell ,  Alvin Berger ,  Kay A. Lawton ,  Christopher Beecher

IPC: G01N33/68

CPC classification number: G01N33/68 ,  G01N33/57434 ,  G01N33/6812 ,  Y10T436/173845 ,  Y10T436/201666

Abstract: Methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early prediction of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for prostate cancer.

Abstract translation: 提供了用于鉴定和评估用作用于早期预测前列腺癌，疾病分级，靶标鉴定/验证和药物功效监测的生物标志物的生物化学和/或基因实体的套件的方法。 还提供了小分子实体的套件作为前列腺癌的生物标志物。

公开(公告)号：US08323680B1

公开(公告)日：2012-12-04

申请号：US10089658

申请日：2000-09-14

Applicant: Alvin Berger ,  Gayle Crozier

Inventor： Alvin Berger ,  Gayle Crozier

IPC: A61K47/00

CPC classification number: A61K31/231 ,  A23L33/115 ,  A23L33/12 ,  A61K31/00 ,  A61K31/16 ,  A61K31/164 ,  A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  A61K31/23

Abstract: A nutritional or therapeutic composition for oral administration which comprises a naturally occurring precursor that is metabolised to a compound having anandamide activity for use as a medicament or nutritive product. In addition the invention includes a method of production of the composition, use of the composition in the manufacture of a nutritional composition for the treatment or prevention of a behavioral disorder; and a method of treatment or prevention of a behavioral disorder which comprises administering an effective amount of the composition. In a preferred embodiment the composition comprises a triacylglycerol having palmitate and arachidonate attached to its backbone wherein arachidonate is at the sn-1 and sn-2 positions.

Abstract translation: 一种用于口服给药的营养或治疗组合物，其包含天然存在的前体，其被代谢为具有用于药物或营养产品的具有酰胺活性的化合物。 此外，本发明包括生产该组合物的方法，该组合物在制备用于治疗或预防行为障碍的营养组合物中的用途; 以及治疗或预防行为障碍的方法，其包括施用有效量的组合物。 在优选的实施方案中，组合物包含具有棕榈酸酯和花生四烯酸连接到其主链的三酰基甘油，其中花生四烯酸酯处于sn-1和sn-2位置。

公开(公告)号：US20080176266A1

公开(公告)日：2008-07-24

申请号：US11840464

申请日：2007-08-17

Applicant: Alvin Berger ,  Imran A. Shah

Inventor： Alvin Berger ,  Imran A. Shah

IPC: C12Q1/02

CPC classification number: G01N33/57484 ,  G01N33/5088 ,  G01N33/5091 ,  G01N2800/42

Abstract: Methods for the measurement and prediction of response to hepatotoxicants and carcinogens through the detection of metabolites in a mammal are provided. The metabolites can be used as biomarkers, including efficacy biomarkers, surrogate biomarkers, and toxicity biomarkers. The methods find use for early prediction of toxicity, target identification/validation, and monitoring of drug efficacy.